A Dose-response of the Effects of Exendin-9,39 on GI Symptoms and Food Intake

NCT02128581 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

3

Enrollment

OTHER

Sponsor class

Conditions

Obesity
Diabetes
Roux-en-Y Gastric Bypass

Interventions

DRUG: Exendin-9,39
OTHER: Saline

Sponsor

Mayo Clinic

Collaborators

[object Object]
[object Object]